Key result
Shenge powder improved left ventricular function and inhibited myocardial fibrosis in rats with post-myocardial infarction heart failure by inhibiting the LOXL2/TGF-β1/IL-11 pathway (P<0.05).
Why the study?
To investigate the effect of Shenge powder on myocardial fibrosis in rats with heart failure after myocardial infarction and its relation with LOXL2/TGF-β1/IL-11 signaling pathway.
Does Shenge powder improve cardiac function and reduce myocardial fibrosis in a rat model of post-myocardial infarction heart failure?
Does Shenge powder improve cardiac function and reduce myocardial fibrosis in a rat model of post-myocardial infarction heart failure?
p-value: p=<0.05
Shenge powder attenuates myocardial fibrosis and improves cardiac function in a rat model of post-MI heart failure, likely via the LOXL2/TGF-β1/IL-11 signaling pathway.
SGP attenuates post-MI fibrosis via LOXL2 pathway in rats; leaves open translation to human HF therapy.
Objective To investigate the effect of Shenge powder (SGP) on myocardial fibrosis in rats with heart failure after myocardial infarction and its relation with lysyl oxidase like protein 2 (LOXL2)/transforming growth factor-β1 (TGF-β1)/IL-11 signaling pathway. Methods Seventy-two SPF male SD rats were divided into blank control group, model control group, SGP small dose group, SGP large dose group, positive control group, SGP large dose+LOXL2 activator group, with 12 rats in each group. Except for blank control group, post-myocardial infarction heart failure was induced by coronary constriction in all groups. Corresponding treatments were given immediately after successful modeling, once a day for 4 weeks. Left ventricular fractional shortening (LVFS) and left ventricular ejection fraction (LVEF) in rats were detected by Color Doppler ultrasound imaging. Levels of IL-1β and IL-6 in serum were analyzed by ELISA method, Myocardial collagen volume fraction (CVF) was evaluated by Masson staining. Expressions of collagen Ⅰ and α-smooth muscle actin (α-SMA) in myocardial tissue were detected by immunohistochemical staining. The mRNA expressions of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinase 1 (TIMP-1) in myocardial tissue were detected by qRT-PCR. Expression of LOXL2, TGF-β1, and IL-11 proteins in myocardial tissue were detected by Western blotting. Results Compared with the blank control group, the LVFS and LVEF of the model control group decreased, the levels of serum IL-6 and IL-1β elevated, the CVF value, the expressions of collagen Ⅰ and α-SMA in myocardial tissue, expressions of MMP-9 and TIMP-1 mRNA, and expressions of LOXL2, TGF-β1, and IL-11 proteins increased (all P<0.05). Compared with the model control group, the LVFS and LVEF of SGP small dose group, SGP large dose group and positive control group increased, the levels of serum IL-6 and IL-1β decreased, the CVF value, the expressions of Collagen Ⅰ and α-SMA in myocardial tissue, expressions of MMP-9 and TIMP-1 mRNA, and expressions of LOXL2, TGF-β1, and IL-11 proteins decreased (P<0.05); while LOXL2 activator reversed the improvement effect of high-dose SGP on myocardial fibrosis in heart failure rats after myocardial infarction. Conclusion Shenge powder may inhibit myocardial fibrosis in heart failure rats after myocardial infarction by inhibiting the LOXL2/TGF-β1/IL-11 pathway.
No takes yet. Share an insight, caveat, or question.
Xie et al. (2025) studied post-myocardial infarction heart failure (n=72). Shenge powder vs. blank control, model control, and positive control was evaluated on Left ventricular fractional shortening (LVFS), left ventricular ejection fraction (LVEF), and myocardial fibrosis markers (p=<0.05). Shenge powder improved left ventricular function and inhibited myocardial fibrosis in rats with post-myocardial infarction heart failure by inhibiting the LOXL2/TGF-β1/IL-11 pathway (P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: